Hyderabad, Feb. 11 -- Syngene International on Tuesday announced a strategic collaboration with Johns Hopkins University to accelerate early-stage drug discovery programs and platform technologies emerging from the university's research laboratories.
The collaboration is anchored in Syngene's SynVent platform, a fully integrated drug discovery and development engine covering discovery biology, medicinal and synthetic chemistry, DMPK (drug metabolism and pharmacokinetics), toxicology, and early development.
The initiative will also leverage Syngene's Connector model, which is designed to link high-potential academic research with strategic investors, pharmaceutical partners, and downstream licensing opportunities, the company said in a rel...